Day One
Tuesday August 31 2021
Day Two
Wednesday September 1 2021
8.00am-6.00pm EDT | 5.00am-3.00pm PDT
DAY 1 PLENARY SESSIONS:
8:00 am Registration
8:15 am Honorary Keynote Presentation
8:45 am Your future CAR-TCR Patient Success-Stories, Delivered by Lonza
9:15 am Industry Leaders’ Fireside Chat
10:00 am Late Breaking Abstracts
Synopsis
Adrian Bot will be presenting UNPUBLISHED DATA: Major Mechanisms and Strategies to Overcome CAR-T Cell Treatment Resistance
Eric Ostertag will be presenting UNPUBLISHED DATA: P-PSMA-101 is a High-Tscm Autologous CAR-T Targeting PSMA Producing Exceptionally Deep and Durable Responses in Castration-Resistant Metastatic Prostate Cancer
10:30 am Speed Networking
DAY 2 PLENARY SESSIONS:
8:15 am Registration
8:45 am Genetic Programming of the Immune System Based on a Comprehensive Approach for Cancer Therapy
9:15 am Driving Commercial Excellence for CAR-T
9:45 am Amassing a Decade of Experience in the Commercialization of a Cellular Therapy Product
10:15 am Next Generation Leaders Fireside Chat
11:00 am Tech Slam
DAY 1 TRACKS:
11:30am-5.30pm
| Discovery | Translation | Clinical Management | Early Phase Development |
Manufacturing | Logistics | Market Access |
Must-Attend Talks
Case Study: Considerations, Challenges, and Infrastructure of an Autologous and Allogeneic Cell Therapy Supply Chain
Laura Deschenes, Head, Supply Chain & Operations, Cell Therapies, Takeda
Integrating Flexibility in CMC Strategy to Manage Risk and Enable Process Improvement at Commercial Scale
Tam Soden, Executive Director & Global Head of Quality Control, Kite: A Gilead Company
Optimizing the End-to-End Patient Journey for Autologous Ex-Vivo T-Cell Therapies During Early Clinical Development
Delfi Krishna, Head of Strategic Operations, Immatics
Achieving Commercial Foresight: What
You Need to Know, and When to Take Action to Achieve Commercial Success
Helen Tayton-Martin, CBO, Adaptimmune
DAY 2 TRACKS:
11.30am-5.30pm
| Discovery | Translation | Clinical Management | Early Phase Development |
Manufacturing | Logistics | Market Access |
Must-Attend Talks
Industrializing Solid Tumor Cell Therapies as Mainstream Medicines
Axel Hoos, SVP, R&D Governance Chair & Therapeutic Area Head Oncology, GSK
Developing Platforms to Deliver an Integrating Transgene In-Vivo with Specific Targeting to T-Cells
Aaron Foster, VP Immunology, Sana Biotechnology
Optimizing Fuel Selection with Enriched Media to Yield ‘Super Metabolizing’ CAR-T Cell Populations, Equipped for Solid Tumor Survival
Roderick O’Connor, Research Assistant Professor of Pathology and Laboratory Medicine, University of Pennsylvania
Translating CAR-Macrophages into the Clinic, with Restricted Anti-Tumor Phenotypes
Michael Klichinsky, Co-Founder & VP Discovery Research, Carisma Therapeutics